



QUANTA Flash™ Celiac



Accuracy

QUANTA Flash celiac assays provide accurate results across multiple markers and isotypes



Chemiluminescence immunoassay (CIA) technology can significantly increase the reportable dynamic range³

- Using Deamidated Gliadin Peptide (DGP) and human-tissue Transglutaminase (h-tTG) in combination helps to stratify patients for biopsy or gluten-free diet¹
- Onboard reagent and calibration curve storage makes testing convenient at any volume
- DGP offers an important complement to tTG, increasing sensitivity for celiac disease^{1,2}
- Fully automated, random access processing with results in as little as 30 minutes

QUANTA Flash™ Celiac

Clinical performance characteristics

Sensitive

- Simultaneous processing of multiple isotypes and markers can help identify patients missed by testing tTG IgA only^{4,5}
- Combinations of tTG and DGP have been shown to detect nearly all biopsy proven celiac patients^{2,6}

Specific

- Specificity >97% means the majority of positives agree with biopsy results⁷
- Dual positivity has been shown to indicate increased positive predictive value⁵

Performance characteristics of QUANTA Flash celiac assays⁷

| Reference # (50 tests/kit) | QUANTA Flash assay | Sensitivity (95% CI) | Specificity (95% CI) | Measuring range (CU) (Cut-off is 20) |
|-------------------------------|-----------------------|-------------------------|-------------------------|---|
| 701103 | tTG IgA | 94.0% (83.5-98.7%) | 98.1% (96.0-99.3%) | 1.9-4965.5 |
| 701108 | tTG IgG | 50.0% (35.2-64.8%) | 98.4% (96.4-99.5%) | 3.8-2560.0 |
| – | DGP Screen* | N/A | N/A | N/A |
| – | DGP IgA* | N/A | N/A | N/A |
| – | DGP IgG* | N/A | N/A | N/A |

QUANTA Flash celiac assays for use on the BIO-FLASH® rapid-response chemiluminescent analyzer

- Full-menu, random-access processing eliminates batching
- On-board reagents and calibration curves make even the most specialized autoimmune tests efficient to perform
- Offers precise quantification and a broad dynamic range using chemiluminescent technology

For more information, visit www.inovadx.com.

*Not available in the United States.

References

1. Volta U, Granito A, Parisi C, et al. Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. *J Clin Gastroenterol*. 2010;44(3):186-190.
2. Sugai E, Moreno ML, Hwang HJ, et al. Celiac disease serology in patients with different pretest probabilities: is biopsy avoidable? *World J Gastroenterol*. 2010;16(25):3144-3152.
3. Martis, et al. Testing for Celiac Disease on the BIO-FLASH Random Access Analyzer. AMLI 2009.
4. Korponay-Szabo. Coeliac antibody testing with deamidated gliadin peptides in difficult patient samples. *Gut*. 2007;56(Suppl III):A109.
5. Dahle C, Hagman A, Ignatova S, et al. (2010). Antibodies against deamidated gliadin peptides identify adult coeliac disease patients negative for antibodies against endomysium and tissue transglutaminase. *Aliment Pharmacol Ther* 32(2): 254-260.
6. Niveloni S, Sugai E, Cabanne A, et al. (2007). Antibodies against synthetic deamidated gliadin peptides as predictors of celiac disease: prospective assessment in an adult population with a high pretest probability of disease. *Clinical chemistry*, 53(12), 2186-92.
7. Respective QUANTA Flash Product Directional Inserts.



Redefining Autoimmunity.

San Diego, CA 92131 USA
PH: +1-858-586-9900 US Toll Free: 1-800-545-9495 FAX: +1-858-586-9911

BIO-FLASH is a registered trademark of biokit S.A. and QUANTA Flash is a trademark of INOVA Diagnostics, Inc. © 2011 INOVA Diagnostics, Inc. All rights reserved.

690200 July 2011 Rev.0